Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

BioSim™ anti-Daratumumab (Human) ELISA Kit

A Sandwich ELISA kit for the Qualitative measurement of antibodies to Daratumumab in human serum or plasma samples

WARNING: This product can expose you to chemicals including TMB, which is [are] known to the State of California to cause birth defects or other reproductive harm.  For more information go to
Catalog #: E4924

Product Details

Cat # +Size E4924-100
Size 96 assays
Detection Method Absorbance (450 nm)
Species Reactivity Human
Applications This Sandwich ELISA kit is used for in vitro Qualitative determination of antibodies to Daratumumab in human serum and plasma samples
Features & Benefits • Cross Reactivity: Except for Daratumumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins
• For in vitro Qualitative determination of antibodies to Daratumumab in human serum and plasma samples
• Assay Precision: Intra-Assay and Inter-Assay CV < 30%
Kit Components • Microtiter Plate
• Positive Control
• Negative Control
• Assay Buffer
• HRP-conjugate Probe
• TMB substrate (Avoid light)
• Stop Solution
• Wash buffer (20X)
• Plate sealers
Storage Conditions 4°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


Daratumumab is a human IgG1 monoclonal antibody that binds with a high affinity to a unique epitope of CD38. CD38 is a type II transmembrane glycoprotein expressed on lymphoid, non-hematopoietic tissues, and myeloid cells. CD38 possesses ectoenzyme activity and plays a significant role in receptor-mediated regulation of cell adhesion and signal transduction. It is expressed at high levels on multiple myeloma cells, thus making it a unique target for therapeutic antibodies targeting multiple myeloma cell surfaces. The monoclonal antibody binds to CD38 on the surface of multiple myeloma cells and induces cell death via multiple mechanisms: complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. The original antibody is approved to treat multiple myeloma in patients who have received at least 3 previous therapies. However, upon administration of the antibody, patients tend to develop an immune response that results in the formation of anti-Daratumumab antibodies, thus adversely affecting the therapeutic response to treatment. BioSim™ anti-Daratumumab ELISA kit qualitatively measures antibodies to Daratumumab in human serum or plasma samples. The kit is based on the Sandwich ELISA principle. Standards and samples (serum or plasma) are added to the microtiter plate coated with Daratumumab. After incubation, the wells are washed. The HRP conjugated probe is added and binds to the antibodies to Daratumumab that is captured by Daratumumab coated on the wells. Following incubation, wells are washed and the enzymatic activity is detected by the addition of TMB chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies to Daratumumab in the sample or standard. The qualitative test results can be evaluated using cut-off values.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.